A Science investigation into the death of a six-year-old girl in China after receiving an experimental brain-directed CRISPR therapy revived ethics and oversight questions for gene-editing clinical use. The report, described through details of the trial’s course, attributes the most likely cause of death to an immune reaction to viral vectors used to deliver the base editor components. The case, involving a base editor intended to correct a faulty gene in brain cells, reportedly included work validated in animals and only modestly characterized risks to the family at the time of consent. The outcome nonetheless resulted in rapid deterioration and death within a week of treatment. For the field, the incident sharpens attention on viral vector immunogenicity management, trial documentation practices, and transparency about adverse events in gene-editing programs. Separately, related reporting from Science Retraction Watch emphasized that the parents sought accountability after the death was not made public, adding pressure on investigators and regulators to demonstrate consistent oversight.